Lymecycline
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584457

CAS#: 992-21-2

Description: Lymecycline is a semisynthetic antibiotic related to TETRACYCLINE.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 465 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-29. Prices are subject to change without notice.

Lymecycline, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584457
Name: Lymecycline
CAS#: 992-21-2
Chemical Formula: C29H38N4O10
Exact Mass: 602.2588
Molecular Weight: 602.641
Elemental Analysis: C, 57.80; H, 6.36; N, 9.30; O, 26.55


Synonym: Lymecycline; Mucomycin; Tetralisal; Limeciclina

IUPAC/Chemical Name: N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine

InChi Key: AHEVKYYGXVEWNO-RKCBBFCZSA-N

InChi Code: InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34,36-37,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14?,15?,16-,21?,28?,29?/m0/s1

SMILES Code: N[C@@H](CCCCNCNC(C(C1=O)=C(O)C(N(C)C)C2CC3C(C)(O)C4=C(C(C3=C(O)C21O)=O)C(O)=CC=C4)=O)C(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Stanisz BJ, Paszun SK, Zalewska A. Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. Acta Pol Pharm. 2014 Jul-Aug;71(4):661-6. PubMed PMID: 25272892.

2: Paszun SK, Stanisz BJ, Gradowska A. Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination. Acta Pol Pharm. 2013 Nov-Dec;70(6):1079-85. PubMed PMID: 24383331.

3: Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Soumelas GS, Loukas YL. Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study. J AOAC Int. 2011 May-Jun;94(3):758-64. PubMed PMID: 21797003.

4: Łukawski K, Jakubus T, Janowska A, Raszewski G, Czuczwar SJ. Enalapril enhances the anticonvulsant activity of lamotrigine in the test of maximal electroshock. Pharmacol Rep. 2013;65(4):1012-7. PubMed PMID: 24145096.

5: Paszun SK, Stanisz B, Pawłowski W. Rapid and simple stability indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison with classic and derivative spectrophotometric methods. Acta Pol Pharm. 2012 Mar-Apr;69(2):193-201. PubMed PMID: 22568033.

6: Narayanam M, Sahu A, Singh S. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. J Pharm Biomed Anal. 2015;111:190-203. doi: 10.1016/j.jpba.2015.03.038. Epub 2015 Apr 3. PubMed PMID: 25890215.

7: Kleinbloesem CH, Van Brummelen P, Francis RJ, Wiegand UW. Clinical pharmacology of cilazapril. Am J Med. 1989 Dec 26;87(6B):45S-49S. Review. PubMed PMID: 2532460.

8: Moisejev VS, Ivleva AY, Gurochkin AB, Kobalava ZD. Effects of cilazapril on cardiac structure and function in hypertension. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S70-2. PubMed PMID: 7700070.

9: Karpov YA, Vilchinskaya MY, Sorokin EV, Podinovskaya VA. Efficacy and tolerability of cilazapril in patients with essential hypertension. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S86-8. PubMed PMID: 7700074.

10: Kellaway GS. A comparison of the efficacy of cilazapril versus cilazapril plus hydrochlorothiazide in patients with mild to moderate essential hypertension. Inhibace General Practice Study Group. Eur J Clin Pharmacol. 1993;44(4):377-9. PubMed PMID: 8513849.

11: Dössegger L, Nielsen T, Preston C, Arabatzis N. Heart failure therapy with cilazapril: an overview. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S38-41. Review. PubMed PMID: 7700063.

12: Belz GG, Breithaupt K, Erb K. Review of studies on the clinical pharmacodynamics of cilazapril. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S14-9. PubMed PMID: 7898090.

13: Rosenthal JR, Osowski U. Tolerability and efficacy of antihypertensive treatment with cilazapril in general practice. Cardiology. 1996 Jan-Feb;87(1):54-9. PubMed PMID: 8631045.

14: Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. J Cardiovasc Pharmacol. 1992 Sep;20(3):451-7. PubMed PMID: 1279292.

15: Johnston GD, Passmore AP. The effects of cilazapril alone and in combination with frusemide in healthy subjects. Br J Clin Pharmacol. 1989;27 Suppl 2:235S-242S. PubMed PMID: 2527536; PubMed Central PMCID: PMC1379753.

16: Madej A, Gierek-Ciaciura S, Haberka M, Lekston-Madej J, Basiak M, Domańska O, Okopień B. Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary results. Ups J Med Sci. 2010 Nov;115(4):249-52. doi: 10.3109/03009734.2010.487951. Epub 2010 Sep 22. PubMed PMID: 20858158; PubMed Central PMCID: PMC2971482.

17: Skoczylas A, Adamczak M, Chudek J, Wiecek A. Cilazapril increases plasma ghrelin concentration in obese patients with arterial hypertension. Endokrynol Pol. 2010 Jan-Feb;61(1):21-7. PubMed PMID: 20205100.

18: Stevenson JG, Chideckel EW. Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension. Clin Exp Hypertens. 1994 Mar;16(2):179-96. PubMed PMID: 8193609.

19: Kleinbloesem CH, van Brummelen P, Francis RJ, Wiegand UW. Clinical pharmacology of cilazapril. Drugs. 1991;41 Suppl 1:3-10. Review. PubMed PMID: 1712269.

20: Tuncer M, Gunes Y, Guntekin U, Gumrukcuoglu HA, Eryonucu B. Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension. Adv Ther. 2008 Feb;25(2):99-105. doi: 10.1007/s12325-008-0012-3. PubMed PMID: 18297254.